ERBB2 and cancer: In tumors with high density of HER2 at the cell surface, the depletion of sortilin-related receptor 1 (SORLA) appears to direct HER2 to the degradative endolysosomal pathway and sensitizes cancer cells to lysosome targeting cationic amphiphilic drugs [30].